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Ⅰ．Introduction
 Lumbar spinal stenosis （LSS） is one of the most 
common diagnoses for low back pain and leg pain 
symptoms for which conservative treatment or surgery 
is performed［1］. LSS is defined as a narrowing of the 
spinal canal, lateral recesses, and/or neural foramina, 
resulting in compression of the neurogenic and vascular 
structures at one or more levels. Compression and 
ischemia of spinal nerves are widely accepted as 
causative symptoms of LSS.
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SUMMARY
Background: Hyperbaric oxygen therapy （HBOT） has an established role in the palliation of 
several conditions. However, few reports of HBOT in patients with lumbar spinal stenosis （LSS） have 
been published. The purpose of this study was to clarify the efficacy and safety of HBOT in patients 
with LSS. 
Methods: This prospective, open-label case control study included 24 LSS patients （19 who 
received HBOT, 5 who did not） diagnosed by clinical symptoms and imaging findings. HBOT was 
conducted 10 times over 4 weeks. Each treatment was conducted for 90 minutes total in a room-sized 
hyperbaric chamber: 15 minutes of pressure with compressed air from 1.0 atmosphere absolute （ATA） 
to 2.0 ATA, 60 minutes of maintenance in which patients breathed 100% oxygen to 2.0 ATA, and 15 
minutes of decompression from 2.0 ATA to 1.0 ATA. The follow-up period was 3 months.
Results: Patients who underwent HBOT showed significant improvement in walking ability, 
pain scale scores and quality of life. In contrast, patients who did not receive HBOT did not experience 
significant changes. One adverse event occurred in 1 patient （5%） in the HBOT group.
Conclusions: We suggest that HBOT can be a safe and an effective conservative treatment for 
LSS patients.
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 Hyperbaric oxygen therapy （HBOT） has an 
established role in the palliation of mandibular 
osteoradionecrosis［2］. The utility of HBOT has also 
been reported for several other conditions, including 
radiation-induced brachial plexopathy［3］, refractory 
hemorrhagic cystitis following pelvic radiotherapy
［4］, radiation myelopathy［2］, radiation-induced optic 
neuropathy［5］, and radiation-induced sacral plexopathy
［6］. However, to the best of our knowledge, no reports 
of HBOT in patients with LSS have been published. 
The purpose of this study was first to clarify a safety of 
HBOT in patients with LSS and second to demonstrate 
the efficacy.
Ⅱ．Materials and Methods
 This prospective, open-label, case-control study, 
which was conducted at a local hospital, evaluated 
a safety and an efficacy of HBOT for the treatment 
of LSS. This study was approved by the hospital’s 
institutional review board, and all participants provided 
informed consent.
 Inclusion criteria were: age ＞20 years and LSS 
diagnosed by clinical symptoms （low back and leg pain） 
and imaging （x-ray and magnetic resonance imaging 
［MRI］） findings. After receiving an explanation about 
HBOT, patients either elected to undergo HBOT （HBOT 
group） or to not receive HBOT but to undergo follow-
up observation （natural course group）. As this was 
a preliminary study to confirm the safety rather than 
the efficacy, all the patients were allowed to keep their 
medication except epidural injection. Of 24 patients, 
the HBOT group consisted of 19 patients （8 males, 11 
females） and the natural course group consisted of 5 
patients （3 males, 2 females）. Mean age at baseline was 
78.2 years in the HBOT group and 73.6 years in the 
natural course group without statistical difference （P＞
0.05）.
 Patients in the HBOT group underwent 10 repetitive 
treatments over 4 weeks. Each treatment was conducted 
for 90 minutes total in a room-sized hyperbaric chamber: 
15 minutes of pressure with compressed air from 1.0 
atmosphere absolute （ATA） to 2.0 ATA, 60 minutes 
of maintenance, during which patients breathed 100% 
oxygen to 2.0 ATA, and 15 minutes of decompression 
from 2.0 ATA to 1.0 ATA.
 At baseline, all patients were evaluated for walking 
distance, step, visual analogue scale （VAS） score 
for low back pain, leg pain and numbness, Japanese 
Orthopaedic Association lumbar score （JOA score）
［7］, and JOA Back Pain Evaluation Questionnaire 
（JOABPEQ） score［8-9］. Three months after study 
initiation, all patients were reevaluated for the same 
outcome measures. Any adverse events were reported 
during the study period.
Statistical Analysis
 Baseline categorical variables and those at 3 months 
were compared using the Wilcoxon signed ranks test. 
Progress in the HBOT and natural course groups were 
compared using the Mann-Whitney U test. Data analysis 
was performed using SPSS Statistics version 16.0 
software （IBM statistics, Chicago, IL）. A p-value＜0.05 
was considered statistically significant.
Ⅲ．Results
 In the HBOT group, walking distance significantly 
improved after 3 months from 297 m to 344 m （P＝
0.0437, Table 1）. VAS scores for low back pain, leg 
Table 1　Clinical data－HBOT group
Baseline
After 3 
months
p-value
Walking distance （m） 297 （304） 344 （314） 0.0437
Step （cm） 49.7 （12.4） 50.7 （11.2） N.S.
VAS （back pain, mm） 46.9 （27.8） 33.3 （21.2） 0.0003
VAS （leg pain, mm） 54.2 （29.1） 33.9 （19.4） 0.0006
VAS （numbness, mm） 56.2 （29.7） 34.4 （21.3） 0.0005
JOA score （points） 14.5 （4.9） 15.6 （5.6） 0.0399
JOABPEQ
Low back pain 42.9 （37.2） 68.5 （29.0） 0.0014
Lumbar function 53.0 （29.0） 64.5 （26.4） N.S.
Walking ability 25.8 （25.5） 42.9 （28.2） 0.0089
Social life function 37.4 （17.0） 46.6 （20.5） 0.0276
Mental health 45.0 （16.5） 47.1 （19.8） N.S.
HBOT: hyperbaric oxygen therapy, VAS: visual analogue 
scale, JOABPEQ: Japanese Orthopaedic Association Back 
Pain Evaluation Questionnaire. Mean （standard deviation）, 
Wilcoxon signed rank test, N.S.: not signiﬁcant.
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pain, and numbness were significantly better after 3 
months （P＝0.0003, 0.0006, and 0.0005, respectively）. 
JOA scores also improved significantly from 14.5 
points to 15.6 points （P ＝0.0399）. Finally, scores 
for JOABPEQ, a parameter of low back pain, walking 
ability, and social life function, significantly improved 
（P ＝0.0014, 0.0089, and 0.0276, respectively）. 
Lumbar function and mental health also improved, but 
not to a statistically significant degree. In contrast, in the 
natural course group, walking distance, VAS, JOA score, 
and JOABPEQ did not change significantly （Table 2）.
 At the baseline, there were not any significant 
differences between the HBOT group and the natural 
course group at all （P ＝＞0.05）. However, three 
mouths later walking distance significantly improved 
in the HBOT group in comparison to the natural course 
group （47 m versus -68 m, P ＝0.0225, Table 3）. 
VAS scores for low back pain, leg pain, and numbness 
significantly more improved in the HBOT group, too （P
＝0.0497, 0.0454, and 0.0275, respectively）. Regarding 
the JOABPEQ, only the social life function parameter 
significantly improved in the HBOT group （8.8 points 
versus -11.6 points, P＝0.0154）.
 One adverse event was noted in 1 （5%） of 19 
patients in the HBOT group: this patient complained of a 
mild buzzing in her ears after the third course of HBOT, 
and declined further treatment. 
Ⅳ．Discussion
 This is the first clinical study to demonstrate better 
outcomes in LSS patients who have received HBOT 
compared to those in patients who have not. Patients 
in the HBOT group showed significant improvement 
in walking ability, pain scale score, and quality of life. 
Adverse event was noted in 5%. Therefore, HBOT 
could be a safe and an effective conservative treatment 
for LSS patients.
 Several possible mechanisms may explain why 
HBOT is beneficial in this patient population. First, 
HBOT promotes repair and generation of new blood 
vessels to the parts of the spinal nerve that have 
been injured and undergone apoptosis, resulting in 
improved metabolism after ischemia［10］. HBOT also 
has an established role in the palliation of mandibular 
osteoradionecrosis［2］. Furthermore, the efficacy of 
HBOT has been reported in several other conditions. 
Patients with vaginal vault prolapse and perineal 
necroses have been treated successfully with HBOT
［11］.  Sensory symptoms were reported to have 
improved in five cases with radiation myelopathy who 
received HBOT, although no change in motor disability 
was seen［2］. A small number of patients with radiation-
Table 2　Clinical data － natural course group
Baseline
After 3 
months
p-value
Walking distance （m） 390 （368） 322 （314） N.S
Step （cm） 50.8 （6.1） 51.6 （7.6） N.S.
VAS （back pain, mm） 44.8 （34.0） 45.0 （28.5） N.S.
VAS （leg pain, mm） 66.8 （26.8） 65.4 （22.3） N.S.
VAS （numbness, mm） 55.8 （41.1） 54.2 （37.5） N.S.
JOA score （points） 12.8 （5.0） 13.0 （3.7） N.S.
JOABPEQ
Low back pain 40.0 （38.4） 42.8 （39.2） N.S.
Lumbar function 56.6 （34.5） 51.6 （23.9） N.S.
Walking ability 48.4 （35.6） 49.8 （23.0） N.S.
Social life function 53.8 （20.4） 42.2 （20.1） N.S.
Mental health 42.6 （20.8） 46.0 （21.9） N.S.
VAS: visual analogue scale, JOABPEQ: Japanese Orthopaedic 
Association Back Pain Evaluation Questionnaire. Mean 
（standard deviation）, Wilcoxon signed rank test, N.S.: not 
signiﬁcant.
Table 3　 Progress of patients in the HBOT and natural 
course groups from baseline to ﬁnal evaluation
HBOT
Natural 
course
p-value
Walking distance （m） 47 （137） -68 （152） 0.0225
Step （cm） 0.9 （4.5） 0.8 （1.8） N.S.
VAS （back pain, mm） -13.7 （15.6） 0.2 （6.1） 0.0497
VAS （leg pain, mm） -20.3 （24.2） -1.4 （12.2） 0.0454
VAS （numbness, mm） -21.8 （41.1） -1.6 （12.2） 0.0275
JOA score （points） 1.1 （2.4） 0.2 （1.5） N.S.
JOABPEQ
Low back pain 25.6 （22.1） 2.8 （32.6） N.S.
Lumbar function 12.6 （25.6） -5.0 （16.0） N.S.
Walking ability 14.7 （22.7） 1.4 （15.7） N.S.
Social life function 8.8 （18.9） -11.6 （8.7） 0.0154
Mental health 6.3 （11.2） 3.4 （9.4） N.S.
HBOT: hyperbaric oxygen therapy, VAS: visual analogue 
scale, JOABPEQ: Japanese Orthopaedic Association Back 
Pain Evaluation Questionnaire. Mean （standard deviation）, 
Mann-Whitney U test, N.S.: not signiﬁcant.
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induced optic neuropathy have been treated with 
HBOT, with some experiencing a reversal of recent 
visual loss［5］. A single case report of a patient with 
radiation-induced sacral plexopathy described lasting 
improvement following HBOT several years after 
the first appearance of sensory and motor symptoms
［6］. All of these effects may require time to occur. 
Compared to the results of several previous animal 
studies in myelopathy and neuropathy, human studies 
involve several influential factors such as age, severity 
of stenosis, social circumstances, prior disability, and 
comorbidities. Moreover, the protocol of HBOT may 
play a role in the prognosis of acute ischemic stroke［12］.
 Based on the results of previous studies, HBOT may 
be associated with several adverse effects, including 
damage to the ears and sinuses due to the pressure, 
seizures, and oxygen poisoning［13-15］. In this study, 
a mild buzzing in the ears was observed in 1 patient 
（5%）. All of the other patients completed the treatment 
protocol. Thus, HBOT appears to be a safe and feasible 
intervention for patients with LSS.
 We have previously used JOA score to evaluate 
low back pain and leg pain［7］. However, this score 
does not incorporate a comprehensive evaluation from 
the patient’s perspective. To resolve this problem, the 
JOA has developed a new score to evaluate low back 
pain, the JOABPEQ, which incorporates several aspects 
from the patient’s experience［8］. This score includes 
five categories （25 items） and has high sensitivity for 
assessing treatment results［9］. Patients in the HBOT 
group experienced significant improvements in low 
back pain, walking ability, and social life function for 3 
months. However, the difference in social life function 
improvement was significantly higher in the HBOT 
group than in the natural course group; this difference 
may be partly attributable to the small number of 
patients in the latter group. Thus, we believe that 
HBOT can improve the quality of life of LSS patients, 
particularly in patients with poor prognoses due to 
serious complications or multiple back surgeries. 
 This study has several limitations. First, the number 
of patients is too small to elicit a strong conclusion. 
Moreover number of patients in two groups is biased, 
because they preferred to HBOT. We must admit that 
this study is preliminary, but our primary goal was to 
confirm the safety of HBOT rather than the efficacy. We 
applied a nonparametric method for statistical analysis 
to eliminate the distribution. Further studies are required 
to confirm these results. Second, patients were followed 
up for only 3 months. Long-term evaluation may be 
necessary to demonstrate the efficacy of HBOT in this 
patient population.
 In conclusion, this study demonstrated better 
outcomes in LSS patients who underwent HBOT 
compared to those who did not. Patients in the HBOT 
group showed significant improvements in walking 
ability, pain scale scores, and quality of life. Adverse 
event was noted in 5%.
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